Current market drug price of Zenocutuzumab

Zenocutuzumab (trade name: Bizengri) is an innovative bispecific antibody drug mainly used to treat patients with advanced non-small cell lung cancer and pancreatic ductal adenocarcinoma carrying NRG1 gene fusions. The drug received accelerated approval from the US FDA in December 2024, becoming a new treatment for this type of rare cancer with poor prognosis. Although zetolizumab is recognized internationally, as of July 2025, it has not been officially launched in mainland China. Therefore, there is no official pricing in the domestic market and it has not been included in the medical insurance catalog.

In the U.S. market, zetolizumab is relatively expensive. According to data from the authoritative medical information website Drugs.com, the specification of zetolizumab injection is 20 mg/mL, and the price per box is approximately 25,363.60 US dollars, equivalent to approximately 18 yuan in RMB. Other channels such as MedChemExpress provide products in different dosage strengths, with prices ranging from 480USD per mg to 10mg 2300USD, showing the high R&D and production costs of the drug. Such high prices put many patients under great financial pressure, especially without medical insurance support.

Currently, there are no generic versions of zetolizumab on the market. As a new type of bispecific antibody, the drug has high technical barriers to development and production and is protected by patents. It is expected that in the next few years, as patent protection gradually expires and related technologies mature, generic drugs may appear on the market, but the specific time is not yet clear. During this period, patients can only rely on original drugs, and most of them are purchased through formal overseas channels, which poses certain challenges to the accessibility of domestic patients.

For domestic patients, if there is a clinical need for the use of zetolizumab, they need to purchase it through regular overseas channels and make medication decisions under the guidance of professional doctors. Due to high drug prices, patients and families need to fully weigh the effectiveness of treatment against the financial burden. In addition, paying attention to the dynamics of domestic drug approval and medical insurance policies will help patients keep abreast of the future availability of zetolizumab in the country. Overall, zetolizumab is a cutting-edge drug for the treatment of NRG1 gene fusion cancers. Although the current price is relatively high and it is not yet available on the market in China, its clinical value and market potential are still highly anticipated.

Reference materials:https://www.drugs.com/